Previous treatment with #adalimumab independently predicts lower #infliximab trough levels at the time of endoscopic remission in pediatric #Crohn disease patients. @crohnscolitisfdn.bsky.social
@gastroadvisor.bsky.socialExplore
@gastroadvisor.bsky.social
@myueg.bsky.social🛡️ Immunogenicity does not compromise outcomes with subcutaneous #infliximab
🔸Anti-drug antibodies (#ADAs) lowered drug levels but not 1-year efficacy or safety
🔸Treatment persistence remained similar regardless of ADA status
Find out more in this UEG Journal article:
👉 https://bit.ly/3UESgZp
